Treatment with daratumumab or isatuximab can rapidly deplete CD38+ regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and Bregs and is associated with clonal expansion of CD4+ and CD8+ T cells in myeloma patients. Here, CD8A is linked to plasma cell myeloma.